Canada GMP's Qualified Person Responsible for Release: What Health Canada Expects From Your Lot Release Program

Most GMP conversations in Canada gravitate toward the flashy stuff — environmental monitoring programs, cleaning validation acceptance criteria, water system qualification. The Qualified Person Responsible for Release rarely gets the same attention. That’s a mistake. Across Canadian GMP inspections, inadequate lot release procedures and poorly defined QPRR accountability show up repeatedly in inspection reports, and the consequences range from 83C letters requiring corrective action to, in serious cases, suspension of Drug Establishment Licence activities.

The role exists because someone has to personally stand behind every lot that enters Canadian commerce. And Health Canada wants to know exactly who that person is, what they reviewed, and whether they had the authority and competence to make that call.

What C.02.014 Actually Requires — and What Most Manufacturers Overlook

Section C.02.014 of Canada’s Food and Drug Regulations is the foundational obligation. It requires the fabricator to establish written procedures for lot release and to designate a person responsible for authorizing each lot before it is distributed for sale. That designation isn’t just administrative — it carries direct regulatory accountability.

Health Canada’s GMP Guidelines (GUI-0001, currently in its third major revision) elaborate on what that review must actually cover. Before authorizing a lot, the QPRR is expected to confirm, at minimum, that:

• All manufacturing steps were completed in accordance with the master production document
• All in-process controls were performed and met specifications
• All finished product testing — potency, identity, purity, dissolution or disintegration as applicable, sterility for sterile products — was completed by a qualified laboratory and yielded passing results
• Deviations from standard procedures were investigated, documented, and closed
• The packaging and labelling complied with the approved specifications
• All required yields fell within established limits

That’s not a light checklist. For a complex solid oral dosage form, a thorough batch record review can easily run to 80–150 pages of documentation. The QPRR is expected to review it — not skim it.

One of the most common gaps inspectors find is what could be called the “paper QPRR” problem: a person is designated on the DEL and signs the lot release certificate, but there’s no evidence they personally reviewed the underlying documentation. When an investigator pulls a batch record and asks the QPRR to walk through their review, that conversation quickly reveals whether the signature was substantive or ceremonial. Health Canada expects the former.

Qualifications, DEL Designation, and the Canada–EU Distinction

Canada doesn’t operate a formal QP certification system the way the EU does. Under EU Directive 2001/83/EC and the corresponding GMP Annex 16, a Qualified Person must hold a specific university qualification in pharmacy, medicine, veterinary medicine, chemistry, pharmaceutical chemistry, or biology; complete at least 2 years of practical experience; and be formally registered with a competent authority in the relevant EU member state. That’s a legally recognized credential with defined prerequisites.

In Canada, the QPRR requirement is embedded in the DEL framework rather than a standalone professional certification. But that doesn’t mean Health Canada is indifferent to qualifications. GUI-0001 expects the QPRR to have education and practical experience appropriate to the product type and manufacturing complexity. For a pharmaceutical solid oral dosage form, that typically means a degree in pharmacy, pharmaceutical sciences, chemistry, or a closely related discipline, combined with hands-on GMP manufacturing or quality control experience — generally a minimum of 3–5 years for products of moderate complexity. For sterile drug products or biologics, the bar is meaningfully higher.

What makes the Canadian system operationally distinct is that the QPRR’s name and qualifications must be included in the DEL application and kept current. If your QPRR leaves the company, you’re required to notify Health Canada of the change. This is an area where smaller manufacturers sometimes slip up — they update their internal org charts and forget that a DEL amendment may be required. An inspection conducted after a QPRR transition without the corresponding DEL update is a straightforward non-compliance finding, and it’s entirely avoidable.

The DEL holder is also responsible for ensuring the QPRR has access to all documentation necessary to perform a meaningful review. That sounds obvious, but in practice, organizations sometimes build systems where batch records are partially assembled in one location, laboratory data is housed in a separate LIMS, and deviation reports live in a third system. If the QPRR has to chase down data across three platforms without a clear review workflow, that’s a quality system design problem — not just a technology inconvenience.

Lot Release in a Contract Manufacturing Arrangement

This is where Canadian GMP gets genuinely complicated for many sponsors. When a DEL holder contracts with a CMO for fabrication or packaging and labelling, the question of who performs lot release — and on what basis — becomes critical.

The short answer under Canadian regulations: the DEL holder retains primary accountability unless a quality agreement clearly and explicitly delegates specific review functions. And even then, certain responsibilities cannot simply be handed off by contract.

Health Canada’s expectations for sponsor/CMO quality agreements are detailed in guidance documents supporting both GUI-0001 and the DEL framework. A compliant quality agreement must specify:

1. Which party performs each element of the batch record review
2. What testing is conducted at the CMO’s site versus at the sponsor’s designated laboratory
3. How deviations are communicated between parties and within what timeframe
4. Who has the authority to authorize the final lot release for sale in Canada
5. How the CMO’s GMP compliance is periodically verified by the DEL holder

That last point catches sponsors off guard more than any other. If your entire manufacturing operation is outsourced to a CMO, you still need a mechanism for verifying that the CMO is operating to Canadian GMP standards. Reviewing their Health Canada inspection history and third-party audit reports annually is a baseline expectation — not a best practice, but a minimum.

Where lot release gets operationally messy in CMO arrangements is when the sponsor’s QPRR is reviewing a batch record they weren’t present to observe being made, relying on documentation prepared by a team they don’t directly manage. The solution isn’t to wave away those limitations — it’s to design the quality agreement and associated oversight program to make that remote review genuinely meaningful. That includes technical transfer documentation, clearly defined manufacturing instructions, agreed in-process specifications, and periodic on-site audits by the sponsor.

For sponsors working with a CMO that holds its own DEL, there’s sometimes a temptation to assume the CMO’s QPRR handles lot release for Canadian distribution. That assumption needs to be tested against the actual written agreements — it can be true, but it must be explicitly documented to be compliant.

What Health Canada Inspectors Flag — and How to Prepare

GMP inspectors conducting DEL assessments in Canada pay close attention to lot release as a systems-level indicator of quality culture. A strong lot release program suggests the manufacturer understands GMP as a living system; a weak one suggests compliance is being treated as paperwork.

The most frequently cited deficiency patterns around lot release authorization include:

Incomplete batch record review documentation. The QPRR signed the certificate, but the batch record review form (or electronic equivalent) doesn’t show which documents were reviewed, when, or what discrepancies were noted and resolved. This isn’t about bureaucratic formality — it’s about demonstrating the review actually happened.

Open or inadequately investigated deviations. A lot released with a deviation investigation still technically “open” is a serious finding. The QPRR is expected to confirm that all deviations affecting the lot have been fully investigated and that a risk assessment has determined the lot meets its specifications. Releasing before that determination is complete violates the intent of C.02.014.

Outdated QPRR qualifications on file. This comes up particularly in organizations that have grown or changed product lines. A QPRR who was well-qualified to release conventional oral solids five years ago may not have the training documentation to support releasing a more complex modified-release formulation today. Inspectors look for continuing education and product-specific training records.

Gaps in CMO oversight. For sponsors with outsourced manufacturing, inspectors will ask to see the quality agreement, the most recent CMO audit, and any corrective actions arising from it. An audit that was due 14 months ago but hasn’t been conducted yet is exactly the kind of gap that turns a routine inspection into an extended review.

Preparing for a Health Canada GMP inspection around lot release means being able to tell a coherent story: here is our QPRR, here are their qualifications, here is how a batch record review is conducted, here is a sample completed package, and here is how we’ve handled the last three deviations that arose before lot release. That narrative should be documentable in under 30 minutes of file review.

Designating Your QPRR Program for Long-Term Compliance

The QPRR isn’t a checkbox. It’s the person whose judgment Health Canada is relying on to keep substandard product out of Canadian commerce. Building that role properly means investing in the right person, giving them the right tools, and documenting their work in a way that can withstand scrutiny.

A few practical priorities for organizations reviewing their lot release programs:

• Audit your DEL to confirm the currently named QPRR matches your actual quality organization — not the person who was in the role when you filed the original application
• Review your batch record review SOPs against GUI-0001 to confirm the scope of review matches current regulatory expectations
• If you use a CMO, pull out the quality agreement and read it against the questions an inspector would ask; identify gaps before they do
• Establish a documented training matrix for your QPRR that reflects the specific product types and dosage forms they’re authorizing for release
• Build in a periodic internal audit of completed lot release packages — not as a policing exercise, but as a genuine quality check on whether the program is working

The QPRR role is one of the places where Health Canada GMP compliance becomes genuinely personal. Done well, it’s also one of the strongest signals to regulators — and to your customers — that your organization takes quality seriously.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• GMP-Compliant Laboratory Testing for Canadian Drug Products — Qalitex Laboratories provides ISO 17025-accredited testing in support of lot release and quality control programs across North America.
• EU Qualified Person Requirements and GMP Lot Release for European Markets — Care Europe covers EU QP obligations, Annex 16 compliance, and the differences in lot release frameworks for manufacturers seeking European market access.